The biopharmaceutical industry in Florida focuses on creating drugs derived from biological sources. It includes product development and commercial services targeting diseases such as cancer, diabetes, and infectious diseases. Florida's climate is conducive for research programs and the state hosts several innovative clinical trials. Moreover, the integration of technology like gene therapy and personalized medicine is becoming prominent. With ongoing advancements and increased investment, the industry is expected to grow significantly in the coming years, shaping the future of healthcare on both local and global scales.

This list features 22 biopharmaceutical companies headquartered across various Florida cities, including Ocala, Miami, and Tampa. The companies vary in size, from small teams in innovative startups to larger firms employing hundreds. Established between the late 1990s and 2016, these companies focus on specialized sectors such as oncology, infectious disease therapy, and regenerative medicine. This concentration of talent and innovation is positioning Florida as a noteworthy player in biopharmaceutical research and development.

Continue reading to discover Florida's top biopharmaceutical companies.

Top 22 Biopharmaceutical Companies Companies in Florida

1. Hemispherx Biopharma, Inc.

• Website: hemispherx.net
• Ownership type: Private
• Headquarters: Ocala, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $1.0M, February 2017
• Founded year: 1966
• Headcount: 11-50
• LinkedIn: hemispherx-biopharma-inc.

Hemispherx Biopharma, Inc., also known as AIM ImmunoTech, is a biotechnology firm based in Ocala, Florida. Founded in 1966, the company is dedicated to the research and development of immunology solutions aimed at treating various diseases, particularly cancer and viral infections. Their flagship product, Ampligen® (rintatolimod), is an immuno-modulator that has demonstrated broad-spectrum activity in preclinical and clinical studies. Currently, Ampligen® is being evaluated in multiple clinical trials, including those for pancreatic cancer and chronic fatigue syndrome. The company has also received funding, with a reported amount of $1 million in 2017, which supports their ongoing research efforts. Hemispherx Biopharma is committed to advancing therapeutic options for patients and healthcare providers, focusing on innovative solutions that address significant medical needs.

2. Xcovery Holdings, Inc.

• Website: xcovery.com
• Ownership type: Venture Capital
• Headquarters: Miami, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, October 2014
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: xcovery

Xcovery Holdings, Inc. is a Miami-based pharmaceutical company founded in 2006, dedicated to improving the lives of patients with advanced cancer through innovative oncology therapies. The company is actively involved in research and development, focusing on targeted therapies that aim to be more effective and less toxic than existing options. Their product pipeline includes Ensartinib, a promising ALK inhibitor for non-small cell lung cancer, and Vorolanib, a next-generation multikinase angiogenesis inhibitor. Xcovery's commitment to advancing cancer treatment is evident in their participation in clinical trials and collaborations with other organizations, including the National Cancer Institute. The company has also secured funding, with a reported amount of $20 million in 2014, which supports their ongoing research initiatives and development of new therapies.

3. Summit Therapeutics, Inc.

• Website: smmttx.com
• Ownership type: Private
• Headquarters: Miami, Florida, United States (USA)
• Employee distribution: United States (USA) 88%, United Kingdom (UK) 11%, Other 1%
• Founded year: 2003
• Headcount: 51-200
• LinkedIn: summit-therapeutics

Summit Therapeutics, Inc. is a biopharmaceutical company based in Miami, Florida, founded in 2003. The company specializes in oncology, focusing on the discovery, development, and commercialization of therapies aimed at improving the quality of life for patients with serious unmet medical needs. Their primary product candidate, ivonescimab (also known as SMT112), is a bispecific antibody designed to target both PD-1 and VEGF, which are critical pathways in cancer treatment. Currently, ivonescimab is involved in two Phase III clinical trials, demonstrating the company's commitment to advancing its oncology pipeline. Summit Therapeutics operates through partnerships and clinical trials, with a significant portion of its workforce based in the United States and a smaller presence in the United Kingdom. The company aims to make a meaningful impact on patient care in oncology, reflecting its mission to address significant health challenges.

4. Romark, L.C.

• Website: romark.com
• Ownership type: Private
• Headquarters: Tampa, Florida, United States (USA)
• Employee distribution: United States (USA) 56%, Puerto Rico 39%, Belgium 5%
• Latest funding: $1.9M, July 2014
• Founded year: 1994
• Headcount: 201-500
• LinkedIn: romark-laboratories-l-c-

Romark, L.C., founded in 1994 and based in Tampa, Florida, is a private pharmaceutical company dedicated to the discovery, development, and delivery of innovative medicines. The company specializes in treatments for infectious diseases, including COVID-19 and chronic hepatitis B. Romark conducts clinical trials to advance its research and has a global presence, with operations in the United States, Puerto Rico, Belgium, Luxembourg, and Australia. They manufacture and market FDA-approved products, notably Alinia (nitazoxanide), and have a strong focus on addressing health challenges through their research initiatives. With over 1,000 patents issued or pending, Romark is committed to advancing medical science and improving health outcomes for patients worldwide.

5. Geropharm

• Website: geropharm.com
• Ownership type: Private
• Headquarters: St. Petersburg, Florida, United States (USA)
• Employee distribution: Russia 96%, Other 4%
• Latest funding: June 2016
• Founded year: 2001
• Headcount: 1001-5000
• LinkedIn: geropharm

Geropharm is a private pharmaceutical company founded in 2001, based in St. Petersburg, Florida, with a significant operational presence in Russia. The company specializes in the development and production of medicinal products aimed at treating chronic diseases, particularly diabetes and obesity. Geropharm has established itself as a prominent manufacturer of insulin, holding a significant market share in Russia. The company operates manufacturing facilities in Obolensk and Pushkin, where they produce active pharmaceutical ingredients and finished dosage forms. Geropharm is dedicated to quality and innovation, adhering to international standards such as GMP and ISO 9001. Their research and development efforts are supported by a dedicated center that focuses on the full development cycle of medicinal products, from initial molecule development to drug registration. Geropharm's portfolio includes a range of products in endocrinology, neurology, psychiatry, ophthalmology, and gynecology, reflecting their commitment to addressing socially important diseases. The company has also made strides in expanding its market reach, with recent approvals for new products and plans for international distribution.

6. QOL Medical LLC

• Website: qolmed.com
• Ownership type: Private
• Headquarters: Vero Beach, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: November 2010
• Founded year: 2003
• Headcount: 51-200
• LinkedIn: qol-medical-llc

QOL Medical LLC, based in Vero Beach, Florida, is a biopharmaceutical company established in 2003. The company is dedicated to enhancing the quality of life for patients suffering from rare diseases through the commercialization of orphan products. QOL Medical markets two FDA-approved treatments: Sucraid® (sacrosidase) Oral Solution, which aids in the digestion of sucrose, and Ethamolin® (ethanolamine oleate) Injection, 5%, used for specific medical conditions. Their focus is on increasing clinical awareness and ensuring patient access to these specialized therapies. QOL Medical actively seeks partnerships to expand its portfolio and improve treatment options for underserved markets, demonstrating a commitment to addressing complex healthcare challenges.

7. Agtc

• Website: agtc.com
• Ownership type: Venture Capital
• Headquarters: Alachua, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $23.5M, October 2022
• Founded year: 1999
• Headcount: 51-200
• LinkedIn: agtc

Agtc, also known as Beacon Therapeutics, is a biotechnology firm based in Alachua, Florida, founded in 1999. The company specializes in gene therapy aimed at treating retinal diseases, with a particular focus on conditions like X-Linked Retinitis Pigmentosa (XLRP), Dry Age-related Macular Degeneration (dAMD), and Cone Rod Dystrophy (CRD). Their lead product, AGTC-501, is currently undergoing a Phase 2/3 clinical trial, showcasing their commitment to advancing treatment options for patients suffering from these debilitating conditions. Agtc's operations include rigorous clinical trials to evaluate the safety and efficacy of their therapies, which are crucial for regulatory approval and market entry. The company has recently secured $23.5 million in funding, reflecting confidence from investors in their innovative approach to gene therapy and their potential to transform patient outcomes in the field of ophthalmology.

8. Expansion Therapeutics

• Website: expansionrx.com
• Ownership type: Venture Capital
• Headquarters: Jupiter, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $6.9M, January 2023
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: expansionrx

Expansion Therapeutics, founded in 2016 and based in Jupiter, Florida, is a biotechnology firm dedicated to creating transformative oral medicines for severe RNA-mediated diseases. The company specializes in small molecules that target RNA, aiming to treat debilitating conditions such as Myotonic Dystrophy, ALS, and Tauopathies. Their innovative SMiRNA™ platform leverages structural biology to identify druggable RNA structures, which allows them to develop effective treatments. With a team of approximately 25 employees, Expansion Therapeutics is actively involved in preclinical and clinical research, working to bring new therapies to patients in need. The company has recently secured funding of over $6.9 million in January 2023, reflecting continued investor confidence in their mission and potential impact in the biopharmaceutical industry.

9. EXUMA Biotech

• Website: exumabio.com
• Ownership type: Corporate
• Headquarters: West Palm Beach, Florida, United States (USA)
• Latest funding: Series B, $41.0M, December 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: f1-oncology

EXUMA Biotech, founded in 2015 and based in West Palm Beach, Florida, is a biotechnology company dedicated to the development of advanced cell and gene therapies targeting autoimmune diseases and cancer. The company is at the forefront of innovation, utilizing proprietary platforms designed to enhance the efficacy and safety of treatments while eliminating the need for traditional chemotherapy. Their rPOC SC platform and GCAR platform are notable for their potential to optimize patient care by allowing for therapies to be administered in less intensive settings. EXUMA has attracted significant investment, securing $41 million in Series B funding in December 2021, which underscores its potential and the confidence investors have in its mission. The company actively collaborates with healthcare providers and patients, aiming to make cutting-edge solutions more accessible in the medical field.

10. Syncromune

• Website: syncromune.com
• Ownership type: Venture Capital
• Headquarters: Fort Lauderdale, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series A, $100.0M, December 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: syncromune

Syncromune is a biopharmaceutical company based in Fort Lauderdale, Florida, founded in 2020. The company is dedicated to developing innovative immunotherapies specifically targeting cancer treatment. Their primary focus is on personalized therapies, particularly through their SYNC-T platform, which combines partial oncolysis of tumors with the infusion of a multi-target biologic drug directly into the tumor. This approach is designed to activate the immune system and promote T cell activation, aiming to improve patient outcomes for those with advanced cancer. Syncromune has recently secured $100 million in Series A funding, which underscores their potential and the interest from venture capital in their research. They are currently advancing their first two candidates, SV-101 and SV-102, through Phase 1 clinical trials, and have received FDA Fast-Track Designation for SV-102, indicating a promising trajectory in their development efforts.

11. Hesperos Inc.

• Website: hesperosinc.com
• Ownership type: Private
• Headquarters: Orlando, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $2.0M, May 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: hesperos-inc.

Hesperos Inc., founded in 2015 and based in Orlando, Florida, is a biotechnology firm that specializes in drug discovery and development. The company is recognized for its innovative Human-on-a-Chip technology, which provides advanced testing services to pharmaceutical and biotechnology companies. This technology allows for a better understanding of human responses to therapeutics, ultimately improving drug efficacy and safety. Hesperos is committed to reducing reliance on animal testing, which is increasingly important in today's ethical landscape. The company has received funding, including a recent grant of $2 million, to support its research initiatives. Hesperos collaborates with various research institutions and has been involved in significant studies, such as those focusing on Alzheimer’s disease and other rare conditions, showcasing its active role in the biopharmaceutical industry.

12. Restem

• Website: restem.com
• Ownership type: Private
• Headquarters: Miami, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: restem-llc

Restem, founded in 2016 and based in Miami, Florida, is a biotechnology company focused on developing cell-based therapeutics and regenerative medicine. The company specializes in innovative therapies utilizing umbilical cord lining stem cells (ULSCs) and natural killer (NK) cell therapies. These therapies aim to treat a range of severe health conditions, including age-associated disorders and autoimmune diseases. Restem is actively involved in clinical trials, including studies for COVID-19 treatment, where their ULSCs have shown promise in reducing inflammation and improving patient outcomes. The company collaborates with healthcare organizations and research institutions to validate the efficacy of its therapies, demonstrating a commitment to advancing medical science and improving patient care.

13. SGN Nanopharma Inc

• Website: sgnnanopharma.com
• Ownership type: Private
• Headquarters: Tampa, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2010
• Headcount: 11-50
• LinkedIn: sgn-nanopharma-inc

SGN Nanopharma Inc. is a Tampa, Florida-based pharmaceutical company founded in 2010. The company specializes in the development of nanomedicines and combination therapies, focusing on chronic diseases that often lack effective treatment options. SGN Nanopharma employs its proprietary Micellar Nanoparticle (MNP) technology to enhance the bioavailability and efficacy of its drug formulations. The company is currently in the clinical stage, with several products in its pipeline, including treatments for dry eye disease and diabetic neuropathy. SGN Nanopharma has established strategic partnerships to support its research and development efforts, including collaborations with academic institutions and contract development organizations. Their commitment to creating impactful, clinically differentiated medicines reflects a proactive approach to addressing significant healthcare challenges.

14. Attralus

• Website: attralus.com
• Ownership type: Venture Capital
• Headquarters: Naples, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $56.0M, February 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: attralus

Attralus is a biotechnology firm based in Naples, Florida, founded in 2019. The company is dedicated to developing innovative therapeutics aimed at treating amyloidosis, a group of diseases characterized by the accumulation of amyloid proteins in organs and tissues. Attralus is pioneering a pan-amyloid removal (PAR) approach, which seeks to directly bind to and eliminate toxic amyloid deposits, potentially transforming treatment outcomes for patients suffering from this condition. Their pipeline includes both therapeutic candidates and diagnostic agents, with a focus on addressing the significant unmet medical needs in the amyloidosis space. Recently, Attralus secured $56 million in Series B funding, underscoring their growth potential and the interest of investors in their mission. The company has also received breakthrough therapy designation for one of its diagnostic candidates, further highlighting its relevance in the biopharmaceutical industry.

15. KemPharm, Inc.

• Website: kempharm.com
• Ownership type: Private
• Headquarters: Celebration, Florida, United States (USA)
• Founded year: 2006
• Headcount: 11-50
• LinkedIn: kempharm-inc.

KemPharm, Inc., now operating under the name Zevra Therapeutics, is a pharmaceutical company based in Celebration, Florida. Founded in 2006, the company specializes in the discovery and development of proprietary prodrugs designed to address serious medical conditions. Utilizing its proprietary LAT® (Ligand Activated Therapy) technology, KemPharm aims to create improved versions of existing FDA-approved drugs and explore new applications for existing compounds. Their product pipeline includes treatments for attention deficit hyperactivity disorder (ADHD), stimulant use disorder, and central nervous system rare diseases. Notable products include AZSTARYS™, a once-daily treatment for ADHD, and APADAZ®, a combination product for pain management. The company remains active in clinical trials and has a clear focus on addressing unmet medical needs in its therapeutic areas.

16. Sofgen Pharmaceuticals

• Website: sofgenpharma.com
• Ownership type: Corporate
• Headquarters: West Palm Beach, Florida, United States (USA)
• Employee distribution: United States (USA) 96%, Colombia 4%
• Latest funding: March 2022
• Founded year: 2002
• Headcount: 51-200
• LinkedIn: sofgenpharma

Sofgen Pharmaceuticals, founded in 2002 and based in West Palm Beach, Florida, is a pharmaceutical manufacturer that specializes in softgel technologies. The company operates as an integrated Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO), offering comprehensive solutions from product development to delivery. Sofgen provides a range of services, including research and development, laboratory testing, and bottling capabilities, catering to both branded pharmaceutical and nutraceutical organizations. With a strong emphasis on quality, Sofgen adheres to stringent compliance standards, holding certifications from the FDA, Health Canada, and other regulatory bodies. Their facility is equipped to handle complex formulations, including hormonal products and high-potency compounds, which are critical in the biopharmaceutical space. Sofgen's innovative approaches, such as their proprietary Unigel™ and Chewgels™ technologies, demonstrate their commitment to advancing drug delivery methods and enhancing patient compliance. The company has built strategic partnerships with key players in the pharmaceutical industry, further solidifying its role in the market.

17. Farcast biodynamics

• Website: farcastbio.com
• Ownership type: Venture Capital
• Headquarters: Brandon, Florida, United States (USA)
• Employee distribution: India 95%, United States (USA) 5%
• Latest funding: Pre-seed, $120,000, July 2019
• Founded year: 2019
• Headcount: 11-50
• LinkedIn: farcast-bio

Farcast Biodynamics, based in Brandon, Florida, is a biotechnology firm that specializes in cancer therapeutics and diagnostics. Founded in 2019, the company employs advanced tumor microdynamics and artificial intelligence to develop precise treatment strategies for cancer patients. Their services are tailored for biopharmaceutical companies and cancer care centers, aiming to improve treatment predictability and patient outcomes. Farcast has processed nearly 24,000 human tumors, which allows them to generate high-quality data that informs their therapeutic and diagnostic developments. The company has also received pre-seed funding of $120,000, indicating initial investor interest in their innovative approach. With a small team of around 44 employees, the company is positioned to make significant contributions to the field of oncology through its proprietary technologies, including the TruTumor and TruSign platforms.

18. Belcher Pharmaceuticals, LCC

• Website: belcherpharma.com
• Ownership type: Private
• Headquarters: Seminole, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: belcher-pharmaceuticals-lcc

Belcher Pharmaceuticals, LLC, founded in 2010 and based in Seminole, Florida, is a pharmaceutical manufacturer that specializes in the development and production of generic drugs. The company has carved out a niche in the production of beta-lactam and cephalosporin antibiotics, catering to a wide range of clients, including major pharmaceutical firms and retailers. With a workforce of approximately 48 employees, Belcher Pharmaceuticals operates from a modern 65,000-square-foot facility in Largo, Florida, where they conduct commercial manufacturing, packaging, and analytical operations. The company emphasizes quality and reliability in its manufacturing processes, ensuring that its products meet stringent FDA standards. Belcher Pharmaceuticals is committed to expanding its product offerings through ongoing research and development, with a focus on difficult-to-manufacture drugs. Their strategic partnerships within the pharmaceutical industry further enhance their capabilities and market reach, allowing them to respond effectively to the growing demand for affordable pharmaceutical solutions.

19. Sancilio and Company

• Website: clearwayglobal.com
• Ownership type: Private
• Headquarters: Stuart, Florida, United States (USA)
• Founded year: 2019
• Headcount: 1-10
• LinkedIn: sancilio-%26-company

Sancilio and Company, founded in 2019 and based in Stuart, Florida, is a private pharmaceutical development firm dedicated to aiding biopharmaceutical startups. The company specializes in providing comprehensive services that cover the entire drug development process, including project evaluations, regulatory compliance, and funding strategies. Their approach is tailored to meet the needs of small to mid-sized companies, helping them navigate the often complex landscape of drug development. Sancilio operates through its subsidiary, Clearway Global, which offers a global network of resources for manufacturing, quality assurance, and clinical studies. The firm prides itself on its ability to create value for its partners by leveraging its extensive experience and connections in the industry. Sancilio's leadership, particularly Dr. Fred D. Sancilio, brings a wealth of knowledge from his previous ventures, enhancing the company's credibility and expertise in the biopharmaceutical field.

20. Sun Microstamping Technologies

• Website: pharmasol.com
• Ownership type: Private
• Headquarters: Clearwater, Florida, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1987
• Headcount: 11-50
• LinkedIn: sun-microstamping-technologies

Sun Microstamping Technologies, known as Pharmasol Corporation, is a private company based in Clearwater, Florida. Founded in 1987, Pharmasol focuses on the pharmaceutical and personal care sectors. The company specializes in research and development, offering services that include formulation, analytical method development, and stability studies. They also provide contract manufacturing services, which cover both primary and secondary packaging. Pharmasol serves healthcare providers and consumers by producing a range of medications and personal care products, ensuring quality and compliance throughout their manufacturing processes. Their commitment to technical innovations and regulatory support highlights their role in facilitating the development and production of effective health solutions.

21. Somerset Therapeutics, LLC

• Website: somersettherapeutics.com
• Ownership type: Private
• Headquarters: Hollywood, Florida, United States (USA)
• Employee distribution: India 100%
• Founded year: 2015
• Headcount: 1-10
• LinkedIn: somerset-therapeutics-llc

Somerset Therapeutics, LLC is a private pharmaceutical company based in Hollywood, Florida, founded in 2015. The company specializes in the manufacturing and supply of affordable generic medicines, aiming to enhance accessibility to healthcare for patients, caregivers, and the healthcare industry. Somerset Therapeutics operates with a small team, primarily based in India, and has developed a strong product portfolio that includes injectables, ophthalmics, oral solutions, and oral solids. The company is dedicated to quality and innovation, ensuring that their products are safe and effective for patients. Their manufacturing facility has received compliance recognition from the USFDA, underscoring their commitment to maintaining high standards in pharmaceutical production. Somerset Therapeutics is also involved in partnerships that enhance their capabilities in research, development, and regulatory affairs, further solidifying their position in the biopharmaceutical industry.

22. Everwell Specialty Pharmacy

• Website: everwellrx.com
• Ownership type: Corporate
• Headquarters: Pensacola, Florida, United States (USA)
• Employee distribution: United States (USA) 90%, India 10%
• Latest funding: January 2022
• Founded year: 2003
• Headcount: 11-50
• LinkedIn: everwell-specialty-pharmacy

Everwell Specialty Pharmacy, founded in 2003 and located in Pensacola, Florida, is a healthcare provider that specializes in innovative pharmaceutical therapies and custom medications. With a team of 29 employees, the company operates a compounding pharmacy that focuses on serving patients with chronic and severe infections. Everwell collaborates closely with healthcare providers to deliver tailored health solutions, ensuring that patients receive medications that meet their specific needs. The pharmacy is accredited by URAC and PCAB, reflecting its commitment to quality and safety in medication preparation. Everwell also offers a range of health-related products and services, including a pharmacist-led follow-up program to enhance patient outcomes. Their onsite lab allows for the production of customized dosages and formulations, addressing the unique challenges faced by patients who may not find effective solutions through traditional pharmacies.

Biopharmaceutical Companies Insights: Key Companies in Florida

Want to Find More Biopharmaceutical Companies Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!